Abstract
p53 mutation remains the most common genetic change identified in human neoplasia. In breast cancer, p53 mutation is associated with more aggressive disease and worse overall survival. The frequency of mutation in p53 is, however, lower in breast cancer than in other solid tumours. Changes, both genetic and epigenetic, have been identified in regulators of p53 activity and in some downstream transcriptional targets of p53 in breast cancers that express wild-type p53. Molecular pathological analysis of the structure and expression of constituents of the p53 pathway is likely to have value in diagnosis, in prognostic assessment and, ultimately, in treatment of breast cancer.
MeSH terms
-
Adenosine Triphosphatases / physiology
-
Ataxia Telangiectasia Mutated Proteins
-
Breast Neoplasms / genetics*
-
Breast Neoplasms / pathology
-
Cell Cycle
-
Cell Cycle Proteins*
-
Checkpoint Kinase 2
-
DNA Helicases / physiology
-
DNA-Binding Proteins
-
Female
-
Genes, p53* / physiology
-
Humans
-
Mutation*
-
Protein Serine-Threonine Kinases / physiology
-
Saccharomyces cerevisiae Proteins*
-
Signal Transduction
-
Transcription, Genetic
-
Tumor Suppressor Proteins
Substances
-
Cell Cycle Proteins
-
DNA-Binding Proteins
-
Saccharomyces cerevisiae Proteins
-
Tumor Suppressor Proteins
-
Checkpoint Kinase 2
-
ATM protein, human
-
Ataxia Telangiectasia Mutated Proteins
-
Protein Serine-Threonine Kinases
-
RAD53 protein, S cerevisiae
-
Adenosine Triphosphatases
-
Rad3 protein, S cerevisiae
-
DNA Helicases